Windward Bio Doses First Patients in Phase II SIRIUS COPD Trial

Why It Matters

The trial marks a critical step toward a potentially differentiated, twice‑yearly COPD therapy, addressing a disease with high hospitalization rates and limited long‑acting biologic options. Success could broaden Windward Bio’s market footprint and validate anti‑TSLP strategies across respiratory diseases.

Key Takeaways

• First patients dosed in Phase II SIRIUS COPD trial
• HBM9378/WIN378 is an ultra‑long‑acting anti‑TSLP antibody
• Trial assesses safety, tolerability, pharmacokinetics in moderate‑severe COPD
• Phase I showed extended half‑life and low antidrug antibodies
• Windward Bio holds global rights except Greater China and parts of Asia

Pulse Analysis

Chronic obstructive pulmonary disease remains a leading cause of morbidity worldwide, driving frequent hospitalizations and a steady decline in lung function. Existing treatments focus on bronchodilation and steroids, yet many patients experience acute exacerbations that erode quality of life. Biologic therapies that modulate the underlying immune pathways, such as thymic stromal lymphopoietin (TSLP), are gaining attention as a means to curb inflammation at its source, potentially reducing flare‑ups and slowing disease progression.

HBM9378/WIN378 distinguishes itself through a proprietary half‑life extension platform and effector silencing, enabling subcutaneous administration only twice a year. In Phase I, the antibody demonstrated a prolonged systemic exposure, minimal immunogenicity, and a clean safety profile—key attributes for chronic respiratory indications where patient adherence is paramount. The ongoing Phase II SIRIUS trial will generate pivotal data on dose‑response, pharmacodynamics, and tolerability in a diverse, global COPD cohort, setting the stage for a potential Phase III program if endpoints are met.

The partnership between Harbour BioMed and Windward Bio underscores a strategic alignment of discovery expertise and commercialization capability. With Windward holding worldwide rights outside Greater China and select Asian markets, the company is positioned to leverage the SIRIUS results alongside parallel asthma studies (POLARIS Phase II/III and a forthcoming Phase III) to build a unified respiratory franchise. Positive outcomes could attract significant investment, expand the anti‑TSLP pipeline, and offer clinicians a novel, ultra‑long‑acting option that addresses an unmet need in COPD management.